Second, because the main clinical first-line treatment for NSCLC is anti-PD-1 therapy combined with chemotherapy, we could not analyze the correlation between the responsiveness to anti-PD-1 or anti-PD-L1 monotherapy and the infiltration of BTLA+CD8+ T cells into tumors. This evidence concerns the gene BTLA and non-small cell lung carcinoma.